A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors

This study is testing an experimental drug called FOG-001 to see if it is safe and effective at treating various types of advanced or spreading cancers. It is designed for people whose cancer has not responded to standard treatments and specifically focuses on tumors affected by certain cell-signaling pathways.

This trial is for adults with advanced solid tumors, including certain types of colon, rectal, liver, or prostate cancers. To be eligible, your vital organs must be functioning well, and you must be physically active enough to undergo treatment.

Participants will receive FOG-001, sometimes in combination with other established cancer therapies, under the close supervision of a medical team. You will undergo regular check-ups, and the team will need to collect small tissue samples (biopsies) to track how the treatment is working.

The study is currently recruiting patients at medical centers in Phoenix, Scottsdale, and Tucson, Arizona. Researchers will monitor your health closely throughout the process to ensure the treatment is being tolerated well.